|
Originally published In Press as doi:10.1074/jbc.M105057200 on November 15, 2001
J. Biol. Chem., Vol. 277, Issue 7, 5514-5523, February 15, 2002
Modulation of Apolipoprotein D and Apolipoprotein E mRNA
Expression by Growth Arrest and Identification of Key Elements in
the Promoter*
Sonia
Do Carmo ,
Diane
Séguin ,
Ross
Milne§, and
Eric
Rassart ¶
From the Laboratoire de biologie moléculaire,
Département des Sciences Biologiques, Université du
Québec à Montréal, Montréal H3C 3P8,
Québec and the § Lipoprotein and Atherosclerosis
Research Group, University of Ottawa Heart Institute, 40 Ruskin St.,
Ottawa, Ontario K1Y 4W79, Canada
Received for publication, June 1, 2001, and in revised form, November 14, 2001
 |
ABSTRACT |
Apolipoprotein D (apoD) and apolipoprotein E
(apoE) are co-expressed in many tissues, and, in certain
neuropathological situations, their expression appears to be under
coordinate regulation. We have previously shown that apoD
gene expression in cultured human fibroblasts is up-regulated when the
cells undergo growth arrest. Here, we demonstrate that, starting around
day 2 of growth arrest, both apoD and apoE mRNA levels increase
between 1.5- and 27-fold in other cell types, including mouse primary
fibroblasts and fibroblast-like and human astrocytoma cell lines. To
understand the regulatory mechanisms of apoD expression, we have used
apoD promoter-luciferase reporter constructs to compare
gene expression in growing cells and in cells that have undergone
growth arrest. Analysis of gene expression in cells transfected with
constructs with deletions and mutations in the apoD
promoter and constructs with artificial promoters demonstrated that the
region between nucleotides 174 and 4 is fully responsible for the
basal gene expression, whereas the region from 558 to 179 is
implicated in the induction of apoD expression following growth arrest.
Within this region, an alternating purine-pyrimidine stretch and a pair
of serum-responsive elements (SRE) were found to be major determinants
of growth arrest-induced apoD gene expression. Evidence is
also presented that SREs in the apoE promoter may
contribute to the up-regulation of apoE gene expression
following growth arrest.
 |
INTRODUCTION |
Unlike most of the other plasma apolipoproteins whose expression
is limited to the liver and/or the intestine, apolipoprotein D
(apoD)1 and apolipoprotein E
(apoE) are expressed in almost all tissues that have been tested
(1-9). In plasma, apoE is associated with very low density,
intermediate density, high density lipoproteins, and chylomicrons, and
it plays an important role in the metabolism of triglyceride-rich
lipoproteins. ApoD, a 29-kDa glycoprotein, is bound to plasma high
density lipoproteins in humans and other species (3, 10-14). ApoE is a
member of the apolipoprotein gene family whereas apoD is a lipocalin, a
superfamily whose members are transporters of small hydrophobic ligands
(15, 16, for review, see Ref. 17). Although apoD has been shown to bind
a number of small molecules, the one or more physiological ligands of
apoD have yet to be definitively identified, and it has been proposed that apoD may have multiple tissue-specific, physiological ligands and
functions (16, 18-22).
ApoE is expressed within the central nervous system and inheritance of
one of the apoe alleles, apoe4, is associated
with an increased susceptibility to Alzheimer's disease. Its gene
expression is induced following experimental injury in the peripheral
nervous system where apoE is thought to play a role in lipid
redistribution during nerve degeneration and regeneration (23).
ApoD is also expressed at high levels in the normal central nervous
systems of various species (2-6, 24), and its expression can be
further increased in pathological conditions. ApoD levels are elevated in the cerebrospinal fluid of patients with Alzheimer's disease, stroke, meningoencephalitis, motor neuron disease, dementia (25), Niemann-Pick disease (26), and schizophrenia (27). Both an increase in
apoD mRNA and immunoreactive protein is detected at sites of
regenerating peripheral nerves (23, 28), in kainic acid-lesioned or
entorhinal cortex-lesioned rat hippocampus (29, 30) and in brain after
traumatic injury (31). In non-neurological pathologies, apoD protein
accumulates in advanced stages of prostate cancer (32) and in the cyst
fluid from women with breast gross cystic disease (33, 34). In
cultured cells, apoD expression can be enhanced by growth arrest and
senescence (35) or by other factors such as steroids (36),
Interleukin-1 (37), 1,25-dihydroxyvitamin D3 (38),
retinoic acid (38), or 25-hydroxycholesterol (39).
The apoD promoter region and non-coding first exon contain a
number of potential regulatory and responsive elements that may be
important modulators of apoD mRNA expression (20, 40). Here, we
report a functional analysis of the 5'-flanking region of the
apoD gene that was designed to identify elements that are important in the induction of apoD gene expression in cells
that undergo growth arrest provoked by serum deprivation. Serum
deprivation and the ensuing growth arrest is believed to elicit a
stress response in cells. We demonstrate that, within the
apoD promoter, a pair of serum-responsive elements (SRE) and
an alternating purine-pyrimidine (APP) stretch that is predicted to
adopt a Z-DNA conformation, are important regulators of apoD expression
in cells in growth arrest. In addition, elements within non-coding exon
1 have an inhibitory effect on apoD gene expression. The
complexity of the regulation of apoD gene expression may
reflect the multifunctional nature of the apoD protein.
 |
EXPERIMENTAL PROCEDURES |
Materials--
The media and supplements used for cell culture
were obtained from Invitrogen. Estradiol, used in the MCF7
adenocarcinoma cell line culture, was kindly provided by Dr. Jacques
Simard (Molecular Endocrinology Laboratory, Centre Hospitalier de
l'Université Lauel Research Center, Québec). The
Total RNA Extraction kit was from Qiagen (RNeasy total RNA kit, Qiagen
Inc., Chatsworth, CA). Radiolabeled nucleotides
([ -32P]dATP, 3000 Ci/mmol) were from ICN and Hybond-N
nylon membranes for Northern blots from Amersham Biosciences, Inc. as
were the restriction endonucleases.
Cell Culture and Growth Arrest Induction--
Primary murine
fibroblasts were derived from C57/Bl and BALB/c mice embryos.
Cells were maintained at 37 °C in Dulbecco's modified Eagle's
medium (DMEM) supplemented with 10% fetal calf serum, penicillin G
(100 units/ml), streptomycin (100 µg/ml), in a 5% CO2
humidified atmosphere and were fed every 2 days with fresh medium.
Growth arrest was achieved by allowing fibroblasts (after 5-10
passages) to reach confluence (this point was called day 0 post confluence).
Immortalized cell lines were obtained from ATCC, Rockville, MD (except
when mentioned), and grown in the following media: mouse NIH/3T3 cells
and COS cells, DMEM-10% calf serum; human 293 cells, DMEM-10%
fetal calf serum; human breast cancer MCF7 cells (obtained from J. Simard), DMEM/F12K-5% fetal calf serum supplemented with 1 mM sodium pyruvate, 2 mM
L-glutamine, and 1 nM estradiol; human
astrocytoma U373MG cells, RPMI/1640-10% fetal calf serum; human
breast cancer ZR75-1 cells (obtained by J. Simard), phenol red-free
RPMI/1640-10% fetal calf serum. All cells were grown at 37 °C in a
5% CO2 humidified atmosphere.
For the analysis of gene expression in sparsely growing cultures, cells
maintained in medium supplemented with 10% fetal calf serum (5% in
the case of MCF7 cultures) were harvested at 50% of confluence. For
analysis of cells in growth arrest, immortalized cell lines at
confluence were subjected to serum starvation. When cells reached 80%
of confluence, the serum concentration was reduced from 10 to 0.2% (or
5 to 0.1% in the case of the MCF7 cultures). After 24 h, medium
(containing 0.2% or 0.1% of serum) was renewed. This time point was
considered as day 0 of serum starvation. Cells were kept in this medium
and harvested at 0, 2, 4, 7, 10, 14, and 21 days post serum starvation
when possible.
RNA Extraction, Northern, and Slot Blot Analysis--
For each
time point, cells were trypsinized, rapidly frozen in liquid nitrogen,
and kept at 80 °C until all time points for a cell line were
collected. For Northern blots, total RNA was extracted and denatured in
formaldehyde/formamide and electrophoresed in 1% agarose gel
containing MOPS (20 mM) and formaldehyde (17%) (adapted
from Ref. 41). Integrity of RNA was controlled by staining the gel with
ethidium bromide. Nucleic acids were transferred to Hybond-N
nylon membrane and UV-fixed for 3 min. For slot blots, lyophilized RNA
was resuspended in a denaturing solution containing SSC (150 mM NaCl and 15 mM sodium citrate), 50%
formamide, and 6.5% formaldehyde. The mixtures were incubated for 15 min at 68 °C and cooled on ice before addition of 2 volumes of 20×
SSC to each sample. Denatured RNA was then filtered under vacuum on a Hybond-N nylon membrane, and each well was washed with 10× SSC twice
(42). Filters were treated as for the Northern blots.
The membranes were prehybridized 1 h at 42 °C in a solution
containing 50% formamide, 3× SSC, 0.5% SDS, 5× Denhardt's reagent and incubated overnight with the probe
([ -32P]dATP-labeled apoD, apoE, or -actin
cDNAs) at 42 °C in hybridizing solution, containing 50%
formamide, 1 M NaCl, 0.5% SDS, 10% dextran sulfate, and
3× Denhardt's reagent. Blots were rinsed for 20 min in 2× SSC at
room temperature (two rinses), washed at 60 °C in 1× SSC, 0.1% SDS
for 45 min, then rinsed in SSC at room temperature before exposure.
Membranes were exposed overnight to Kodak XAR-5 X-Omat films at
80 °C with an intensifying screen (Coronex Lighting Plus, E.I. du
Pont de Nemours and Co., Wilmington, DE). Autoradiographs were scanned
on a Personal Densitometer from Molecular Dynamics (Sunnyvale, CA), and
optical densities were measured. For each value, the optical density
measured for each apolipoprotein tested was divided by that of the
-actin mRNA. The ratio obtained from sparse cultures was given
an arbitrary value of one.
Human ApoD and ApoE Promoter-luciferase
Constructs--
Heterologous luciferase (LUC) reporter gene
constructs containing progressive deletions of the apoD gene
5'-flanking region were made by classic methods. The cloning of 10 kbp
of upstream sequences has already been reported (40). The 1176
construct was first digested by combinations of restriction
endonucleases as shown in Figs. 4 and 5 to remove portions of the
sequence. Position +1 corresponds to the transcription start site. The
truncated apoD promoter was cloned upstream of the firefly
luciferase coding region into the pXP2 promoter-less vector. Constructs
2128 and 1676 were obtained by adding, respectively, fragments
XbaI/HindIII or
EcoRV/HindIII of the 5'-flanking region of
apoD upstream to the 1176 construct.
PCR-amplified portions of the apoD promoter corresponding to
the regions 816/ 597, 676/ 471, 548/ 321, 397/ 176, and
266/ 51 were cloned in the correct orientation upstream of position
179 in the 179 construct, thereby, creating the deletion constructs illustrated in Fig. 5. Primer sequences for generation of the segments
were as follows. The 5' limit of each primer and the 3' limit of the
complementary primer are indicated at the left of the sequence: 816,
CCT GGG TTT AAG TCC ACA CT, and 617, CTT TCT CCA CCA GAG CCA GA;
676, TTAGCCCCAGTTGTTAGAGA, and 487, CTG ACT CCA CTA ATG GGA GT;
548, GAG AAA GCC AGC TTT GAC TC, and 351, TTT TTT TGG TCA GAA TGC
AC; 397, TGC AAC ACG TCC TGC TGG AA, and 206, TTT CGC GCG TGT GTG
TGT GT; 266, TCT CTC GCA CAC ATA CCC AC, and 71, ACT TTT CAT GCA
TGC CAC GC. Constructs containing exon 1 were made using the same approach.
ApoE promoter constructs containing five or three SRE-like
sequences, apoE-5SRE and apoE-3SRE, were created by cloning,
respectively, SmaI/BamHI ( 620 to 15) and
BamHI ( 366 to 15) fragments of pLIV10 plasmid (John
Taylor, Gladstone Institute of Cardiovascular Disease, San Francisco,
CA) into the pXP2 polylinker region.
Constructs presented in Fig. 6B containing permutations of
one or more SRE and APP were made as follows: The APP sequence was
obtained by PCR from the 558 construct using oligonucleotides 286,
TCT CTC GCA CAC ATA CCC AC, and 206, TTT CGC GCG TGT GTG TGT GT. SREs
were excised from the commercial plasmid p5SRE (Stratagene). Both were
cloned upstream of 179 construct in pXP2 vector.
SRE Mutagenesis and APP Deletion--
The two SREs present in
the apoD promoter were mutated by oligonucleotide-directed
PCR mutagenesis (Table I). The GG
residues of the core sequence (CCA/TN5GG) have been changed to
TT as described previously (43). Four complementary mutated primers and
two vector-specific primers were used in two-step PCR. SRE1 ( 474 to
465) was mutated using two complementary oligonucleotides CAT GTT CCA
CTT CAT TAA ATG A and TCA TTT AAT GAA GTG GAA
CAT G. SRE2 ( 502 to 493) was mutated using TGA CTC CCA TTA
GTT TAG TCA G and CTG ACT AAA CTA ATG GGA GTC
A. The mutated nucleotides are underlined.
View this table:
[in this window]
[in a new window]
|
Table I
Site and orientation for the serum response element (SRE) consensus
sequence CC(A/T)NNNNNGG in promoter regions analyzed in this study
|
|
The APP element was deleted using two oligonucleotides that share a
region of complementarity. One of the oligonucleotides (GTT AAC ACT CGC
GAA TAG AGA GAG AGA GAG TA) also included a segment that was
complementary to sequences upstream of the APP, whereas the
oligonucleotide (ATT CGC GAG TGT TAA CAA AAC AAT ATC TCA TT) included a
segment that was complementary to a sequence that was downstream of the
APP. The two vector-specific primers were the reverse and universal
primers of pBluescript. Double and triple mutants were constructed by
the same technique using sequential mutagenesis. All of the
luciferase reporter constructs were sequenced to confirm
that the desired mutation was present and that no other alterations had occurred.
DNA Sequencing--
Nucleotide sequencing was performed on
single-stranded plasmid templates using the Sanger method (44) and T7
polymerase enzyme as recommended by the suppliers (Amersham
Biosciences, Inc.).
Transfection and Transient Expression--
NIH/3T3 and 293 cells
were transfected by the calcium phosphate-DNA coprecipitation method
(45) with sterile plasmids (10 µg total: 9 µg of the tested plasmid
plus 1 µg of the control plasmid pRSV GAL). Twenty-four hours
later, cells were rinsed twice with phosphate-buffered saline and
culture medium was changed for medium supplemented with 10 or 0%
serum. Cells were harvested 4 days after transfection for luciferase
and -galactosidase assays. A time-course analysis showed that this
delay was optimal for apoD expression analysis (see Figs. 1 and 2).
Luciferase and -Galactosidase Assays--
Cells were washed
with phosphate-buffered saline before adding 100 µl of Tris-HCl, 0.25 M, pH 7.8. Cells were then scraped with a cell lifter,
transferred into microcentrifuge tubes, and lysed by three cycles of
freeze-thawing as described previously (46). After centrifugation at
12,000 × g for 5 min, lysates were stored at
20 °C. Luciferase assays were performed with a Wallac 1404 luminometer using the conditions and buffers recommended by the
Luciferase assay system (Promega). -Galactosidase assays were done
as follows: each sample (30 µl) was adjusted to a final concentration
of 1 mM MgCl2, 45 mM
-mercaptoethanol, 0.88 mg/ml o-phenyl- -D-galactopyranoside, and 0.1 M sodium phosphate (pH 7.5) and incubated at 37 °C for
30 min. Reactions were stopped by the addition of
Na2CO3 to a final concentration of 625 mM, and the optical density was read at 420 nm (42). The
plasmid pSV2LUC was included as a control promoter. The results were
standardized by calculating promoter activity relative to that of the
co-transfected internal control plasmid pRSV GAL. Each value is the
average of at least three independent experiments performed in triplicate.
Electrophoretic Mobility Shift Assays--
50 ng of sense
oligonucleotide was 5'-end-labeled with T4 polynucleotide kinase and
[ -32P]ATP and annealed with 200 ng of the
complementary oligonucleotide. Nuclear extracts from growing or from
4-day serum-starved NIH/3T3 fibroblasts were prepared according to the
method of Dignam et al. (47). Nuclear extracts were analyzed
by gel shift assays as described previously (48). 5 µg of nuclear
extract were added to 0.8 ng of the labeled double-stranded
oligonucleotide, and, after a 20-min incubation at room temperature,
the mixture was run on a 6% acrylamide, non-denaturing gel in 0.5×
TBE, at 150 V for 90 min. The dried gels were autoradiographed on Kodak
X-Omat films. For competition assays, a 25-fold excess (20 ng) of cold double-stranded oligonucleotide was added before addition of the nuclear extract. The sense strand sequences of the oligonucleotides used are: SRE1, TGA CTC CCA TTA GTG GAG TCA G; SRE2, CAT GTT CCA CTT
CAG GAA ATG A; c-fos SRE, GGA TGT CCA TAT TAG GAC ATC TGC; UNR (unrelated sequence), CCA AAC AGG ATA TCT GTA ATA AGC AG. The
mutated SRE1 and SRE2 oligonucleotides, called mSRE1 and mSRE2, respectively, are identical to those used for the mutagenesis (section
here above).
 |
RESULTS |
ApoD and ApoE mRNA Expression in Growth-arrested Cell
Lines--
The expression of both apoD and apoE was first analyzed in
primary cell lines. Primary mouse embryonic fibroblast cultures from
BALB/c and C57/Bl mice were collected in growing conditions (50% of
confluence), and at different times after they reached confluence. For
both strains, apoD mRNA expression was very low in growing cells
and reached a peak at day 4 of growth arrest (Fig.
1). There was no apoE mRNA expression
in sparse culture and detectable expression appeared at day 4 in BALB/c
and in C57/Bl primary fibroblasts, although apoE expression was much
lower in the latter.

View larger version (67K):
[in this window]
[in a new window]
|
Fig. 1.
ApoD and apoE mRNA expression in primary
mouse embryonic fibroblast cultures in growth arrest stage caused by
cellular confluency. In each lane 10 µg of poly(A)+
RNA was loaded onto a gel. The first lane is RNA from sparse cultures,
the following lanes are, respectively, RNA from cultures at day 0 (i.e. confluence), days 4, 7, 10, 14, and 21 post-confluence. Blots were hybridized with mouse apoD, rat apoE, and
rat -actin cDNAs. For the graphic representations, films were
scanned and expression is expressed in relative OD values.
Black and white bars represent apoD and apoE
expression, respectively. At each point, the expression value
represents the ratio of the "apoD (or apoE) expression/ -actin
expression." For each cell line, a value of 1 was given for the
expression in growing cultures.
|
|
Immortalized cell lines were also tested for apoD and apoE expression
in growth arrest. In murine NIH/3T3 fibroblasts (Fig. 2), the expression pattern was very
similar to that of the primary mouse fibroblasts, reaching a peak
at day 10 with a 15-fold induction. ApoE expression was quite similar
to that observed in C57/Bl fibroblasts. Several other cell lines were
also tested but, to better quantify apoD and apoE mRNA expression,
total RNA from various cell lines were slot-blotted and expression of
apoD and apoE relative to -actin gene expression was
measured on a densitometer (Fig. 2). In ATCC 293 human fibroblast-like
cells, both apoD and apoE expression increased continuously to reach a
5-fold induction by day 21 of growth arrest. In COS cells (Fig. 2),
apoD gene expression increased by 3- and 12-fold at 4 and 10 days, respectively, after growth arrest. ApoE expression in COS cells
showed a similar response to serum deprivation.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 2.
ApoD mRNA expression in immortalized cell
lines after growth arrest caused both by serum starvation and cellular
confluence. In each lane, 50 µg of total RNA was loaded. The
first is RNA from growing cultures in 10% serum; the following lanes
are, respectively, RNA from cultures at day 0 (i.e. serum at
0,2%), days 2, 4, 7, 10, 14, and 21. Blots were hybridized with mouse
or human apoD cDNA, rat apoE cDNA, and rat -actin cDNA
as a control. Graphic representation is as in Fig. 1. The cell lines
tested are: A, NIH/3T3 murine fibroblasts; B,
human 293 fibroblast-like; C, COS, simian kidney cells;
D, U373MG, human astrocytoma; E, MCF7, human
mammary cancer cells; and F, ZR75-1, human mammary cancer
cells. For each cell line, a value of 1 was given for the expression in
growing cultures.
|
|
We also measured mRNA expression in several cancer cell lines. ApoD
expression has been detected in mammary carcinomas (34), in prostate
cancers (32), and in the cyst fluid from women with breast gross cystic
disease (49). In cell lines, apoD expression was modulated by
estrogens, androgens, 25-hydroxycholesterol, steroids, interleukins,
retinoic acid, and 1,25-dihydroxyvitamin D3 (36-39, for
review see Ref. 17). We were therefore interested in testing the effect
of serum starvation on some of the cells used in these studies.
Expression levels were measured during growth arrest in U373MG, a human
astrocytoma, in MCF7 and ZR-75-1, two human breast cancer cell lines
of epithelial origin, and in LNCaP, a prostate cancer cell line. In
U373MG, expression of both apoD and apoE was modulated by growth
arrest. Four days after serum deprivation, apoD mRNA levels
increased 12- and 27-fold at day 21 and apoE mRNA levels increased
7.5-fold at day 4 and 20-fold at day 21 (Fig. 2D). A totally
different pattern of expression was observed in the breast cancer cell
lines. In MCF7 cells, apoD gene expression was inhibited
following growth arrest and was completely abolished by day 10 (Fig.
2E). However, apoE mRNA expression was induced by growth
arrest as in the other cell lines tested with an 8-fold induction at
day 14. The ZR75-1 breast cancer cell line and LNCaP prostate cancer
cells revealed no significant variation in apoD or apoE expression
after growth arrest (Fig. 2F and results not shown).
Analysis of the Promoter Region and Effect of the Non-coding Exon
1--
The apoD promoter is rich in potential regulatory
elements (Ref. 40, Fig. 3). To identify
elements that regulate the expression of apoD in fibroblast cultures in
growth arrest, we constructed mutants by making progressive deletions
from the 5'-end starting at 2128 in the sequence. Each construct was
made with and without the 66-bp non-coding exon 1 in the pXP2
expression vector that encodes the luciferase gene. Exon 1 contains a transforming growth factor- inhibitory element, an
element that has been identified as a transcription inhibitor in other
genes. Each construct was co-transfected in 293, 293T, and NIH/3T3
cells with a construct containing the -galactosidase
gene. After transfection, the cells were cultured in either
serum-containing medium or serum-free medium. In these conditions, both
serum deprivation and achievement of confluence contribute to growth
arrest. The luciferase activity was analyzed after 4 days, and the
results were normalized for the -galactosidase activity.

View larger version (75K):
[in this window]
[in a new window]
|
Fig. 3.
Sequence of, and potential regulatory
elements within, the 5'-flanking region and exon 1 of the
apoD gene. The exon 1 sequence is presented in
italics. AP-1 and AP-2, activation
proteins 1 and 2; APRE2 and 3, acute
phase-responsive elements 2 and 3; CP2, erythroid cell
nuclear factor; E47, recognized by TAL-1;
E2F, early adenovirus transcription factor;
E4BP4, Z-DNA binding proteins of bZIP family;
ERE, estrogen-responsive elements; FSE,
fat-specific element; GRE, glucocorticoid-responsive
element; IK-1, Ikaros-1; IRF-1, interferon
regulatory factor; MZF-1, myeloid zinc finger protein;
MRE, metal-response element; NFK-B, nuclear
factor kappa B; PRE, progesterone-responsive element;
RFX, X-box binding protein; RORA1, steroid
hormone nuclear receptor (retinoic acid) alpha1; SDR,
sterol-dependent repressor; STAT,
ligand-activated transcription factor; STRE, stress response
element; TAL-1, T-cell acute lymphoblastic leukemia;
T IE, transforming growth factor 1
inhibitory element; TRE, thyroid-hormone response
element.
|
|
With the first construct ( 2128/ 4), containing the entire promoter
region, growth arrest resulted in a 6-fold induction of promoter
activity (Fig. 4B). Induction
was also observed with the 1676/ 1, 1176/ 1, and 558/ 1
constructs but was lost when the sequence 558 to 179 was deleted,
which suggests that major regulatory elements are located in this
region. Very similar results were obtained with 293, 293T, and NIH/3T3
cells. Region 179 to 4 seems to contain the minimal promoter
activity, and no major differences were observed in luciferase activity
between growing conditions and growth arrest in cells that were
transfected with the 179/ 4 construct. Also, region 32 to 4,
which contains only the TATA box gives very low levels of activity. The
effect of exon 1 on gene expression was consistent but relatively
minor, with the notable exception of the 1176 construct that showed an important reduction (4-fold; p < 0.0001) of
expression both in the presence and absence of serum.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 4.
A, representation of the human
apoD promoter with its principal regulating elements.
E, estrogen-responsive elements (ERE); S,
sterol-dependent repressor (SDR); A3, acute
phase-responsive element 3 (APRE3); F, fat-specific element
(FSE); AP1, activation protein 1; G,
glucocorticoid-responsive element (GRE); A2, acute
phase-responsive element 2 (APRE2); APP, alternating
purine-pyrimidine stretch; P, progesterone-responsive
element (PRE). Triangles represent serum-responsive
elements, and the arrow is the TATA box. GC
stands for the GC box. B, a series of heterologous
luciferase reporter constructs were made that contained
progressive deletions of the 5'-flanking regions of the apoD
gene with or without the non-coding exon I. After transfection, cells
were cultured in media with or without 10% serum supplementation and
were assayed for luciferase activity after 4 days. Different
letters indicate statistically significant results
(p < 0.02). C, luciferase activity was
determined in cells that had been transfected with a SV40 viral
promoter luciferase reporter construct that did, or did not,
include apoD exon I in sense or antisense orientations or a plasmid
sequence of a length similar to that of apoD exon 1 (linker). Each
value represents the mean ± S.E. of at least three experiments
performed in triplicate.
|
|
To further analyze the exon 1 inhibitory effect, the 4 to + 71 fragment was cloned in both orientation between the SV40 early promoter
and the luciferase gene (Fig. 4C). A linker of
the same length was also cloned in the same position to compensate for the spacing effect between the promoter and the reporter gene. Luciferase activity was measured 5 days after transfection in growing
cells. Similar results were obtained in growth-arrested cells (results
not shown). As can be seen in Fig. 4C, the construct containing exon 1 in the sense orientation showed a 4-fold decrease of
promoter activity as had been observed for the human promoter (construct 1176). This effect is not due to the spacing but to the
exon 1 itself, because replacing the exon sequence by a linker of
identical length does not reduce the SV40 promoter activity. Also, the
inhibitory effect seems to be associated with the exon sequence,
because the antisense construct also shows a 4-fold decrease of
promoter activity. It is interesting to note that the most important
reduction of activity was observed in the 1176 construct only,
suggesting that some elements presents between 1176 and 558 could
interact with the exon 1 but only when upstream sequences are absent.
Mapping of the Functional Elements Associated with the Growth
Arrest--
Results of Fig. 4B revealed a severe loss of
promoter activity both in presence of serum and in growth arrest when
the region 558 to 179 was removed. Region 179/ 4 does not have
any remaining promoter inducibility. If we look at the -fold induction
for the first six constructs in Fig. 5,
it seems that the primary determinants for the induction of expression
during growth arrest are located between nucleotides 558 and 179
with a 27-fold induction. However, the promoter activity of the four
first constructs in the absence of serum is quite similar, and the
differences in the magnitude of induction (6- to 27-fold) are due
mainly to variation of the activity in the presence of serum (Fig. 5).
The region 558 to 179 contains several potential regulatory
sequences, including an AP1 site, two serum-responsive elements (SRE),
an alternating purine-pyrimidine stretch (APP), three
steroid-responsive elements (progesterone (P), estrogen (E), and
glucocorticoid (G)), and two acute phase-responsive elements (Fig. 3).
The SREs could be considered as prime candidate elements for the
induction of apoD expression by serum deprivation, because this
sequence has been clearly associated with cell growth in other models
(50).

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 5.
A series of heterologous
luciferase reporter constructs was made that contain
progressive deletions of the 5'-flanking regions of the apoD
gene. These constructs were transfected into NIH/3T3 cells,
and luciferase activities were assayed 4 days after transfection in
cells maintained in media with (gray bars) or without
(black bars) 10% serum. Induction represents the
ratio of luciferase activities of cells maintained without serum to
that of cells maintained with serum. Each value represents the
mean ± S.E. of at least three experiments performed in
triplicate.
|
|
To further analyze the importance of the region 558 to 179 of the
promoter, we created a series of apoD promoter-reporter constructs that contained internal deletions in this region (Fig. 5).
The results demonstrate the complexity of the regulation of apoD
expression and likely reflect the abundance of regulatory elements
within the apoD promoter. As expected, deletion of the 558/ 179 region abolished induction while minimal promoter activity was retained. Larger deletions ( 799/ 179 and  1052/ 179)
resulted in reduced promoter activity in the presence or absence of
serum. Internal deletions within the 558 to 179 region had variable effects. Dividing the region in two parts with deletions
( 558/ 352 and  352/ 179) reduced the magnitude of induction
to 2- and 3-fold, respectively. This would imply that more than one
regulatory element contributes to induction of apoD gene
expression following growth arrest. The reduced induction with the
 352/ 179 construct suggests a possible participation of the APP.
Deletions 473/ 191 and 525/ 310 showed an intermediate behavior.
The  473/ 191 lacks the APP sequence and one SRE, whereas the
 525/ 310 retains the APP but lacks the two SRE sequences. To
refine the analysis, PCR-amplified portions of the apoD
promoter were cloned upstream of the minimal-179/ 4 promoter construct
(Fig. 5). Again, the constructs were transfected into NIH/3T3 cells
that were then placed in the presence or absence of serum. The results
are consistent with those presented above and suggest an important role
for the APP as a regulator (construct 266/ 51). However, the
addition of the APP-containing PCR fragment to the 179 to 4 basal
promoter does not restore the entire -fold induction observed with the
region 558 to 179. It is probable that other elements such as the
SRE and/or the AP-1 may contribute to the full promoter induction.
Importance of SRE and APP Regions--
Because the previous
results seem to point out the importance of the APP and the SREs in the
apoD induction in growth arrest, we decided to mutate the two SREs
present in the region 558 to 179 and also to delete the long
stretch of alternating purine-pyrimidines. Fig.
6A shows that mutation of one
or both of the SRE elements results in a relatively small, but
significant, decrease in the induction of expression of the reporter
gene upon growth arrest. A much greater effect is observed when the APP
region is deleted ( APP). When compared with cells that were
transfected with the wild type 558 construct, induction following
growth arrest in cells that received the APP construct was reduced
from 27- to 5-fold (p < 0.0001). When either or both
of the SRE sites are mutated in the APP construct, there is a
further decrease in induction.

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 6.
A, site-directed mutagenesis and
deletion of the SRE and APP regions. Either or both of the SRE elements
were mutated and/or the APP tract was deleted in the 558/ 4
apoD promoter-reporter construct and the plasmids were
assayed for luciferase activity after transfection into NIH/3T3 cells.
Gray and black bars represent luciferase activity
in growing and growth-arrested cells, respectively.
Induction is the ratio of luciferase activity of cells in
growth arrest to that in growing cells. Letters at the right of
the induction numbers represent statistical significance;
different letters indicate statistically different -fold
induction (p < 0.003). B, importance of the
number and orientation of the SRE and APP regions in the
apoD promoter. Different copy numbers of SRE
(arrowheads) and APP (P) elements
(wave), in sense and antisense (as) orientations,
were placed in front of the 179/ 4 apoD promoter-reporter
construct. After transfection of the plasmids into NIH/3T3 cells,
luciferase activity was determined under conditions of cell growth
(gray bars) or cell arrest (black bars).
C, importance of SREs in the apoE promoter.
NIH/3T3 cells were transfected with 620/ 14 (with 5 SREs) and
365/ 14 (3 SREs) apoE promoter-reporter constructs and
luciferase activity was determined under conditions of cell growth
(gray bars) or cell arrest (black bars) and
compared with cells that had been transfected with the p5SRE-luc
plasmid or with 178/ 4 apoD promoter-reporter constructs
that contained either three or five copies of the SRE element. Each
value represents the mean ± S.E. of at least three experiments
performed in triplicate.
|
|
To better understand the effect of these elements out of their complex
environment, constructs were made that contain combinations of the
number and the orientation of these elements upstream of the minimal
promoter construct 179 to 4 (Fig. 6B). The addition of
three and five SRE in front of the minimal promoter resulted in an
increased -fold induction of 13 and 17, respectively, suggesting an
additive effect of this element. Also, the orientation of the SRE has
no or little effect on the promoter activity (5SREas, Fig.
6B), and such elements are present in the two orientations both in the apoD and apoE promoters. The addition
of one or two APP stretches had variable effects depending on the
orientation of the sequence. In the sense orientation, the magnitude of
the induction increased to 7.4- and 16.7-fold, respectively, again suggesting a copy-number additive effect. However, when the APP units
were placed in the opposite orientation, either head to head or tail to
tail, the promoter activity in growth-arrested conditions was greatly
reduced. Because both SRE and APP elements are present in the
apoD promoter, we have analyzed combinations of the elements
for their capacity to induce apoD expression under growth-arrested
conditions. A combination of three or five SREs with one APP showed
inductions of 17- and 21.5-fold, respectively. Surprisingly, if the
five SRE are placed in the opposite orientation, the induction drops to
5-fold suggesting an orientation-dependent synergism
between the SRE and the APP. This dependence on orientation is lost,
however, if the APP is moved upstream of the SRE (compare P-5SRE with Pas5SRE, Fig. 6B). A
duplication of the APP sequence in the presence of five SREs was also
dependent upon the APP orientation because we obtained the highest
induction (26-fold) with a construct containing 5SRE followed by two
APP in the sense orientation and a much lower induction (6-fold) when
the 2-APP sequences were in the opposite orientation.
SRE Elements in the ApoE Promoter--
We have shown that apoE
expression is, as that of apoD, induced in growth arrest.
Interestingly, five SRE elements are present in the apoE
promoter within the first 620 bp of the promoter whereas no alternating
purine-pyrimidine stretch is found. A construct containing the 620 bp
of the apoE promoter upstream of the luciferase reporter gene showed a 12-fold induction of expression in growth arrest
conditions, similar to that observed with the commercial construct
containing a basic promoter joined to five SRE tandem repeats (Fig.
6C). The removal of the sequence 620 to 366 that contains two SRE elements caused a decrease of induction in apoE expression to 3-fold. Thus, the SREs in the apoE promoter
could contribute to the induction of apoE gene expression
that occurs following growth arrest, although we cannot rule out the
possibility that other regulatory elements were also removed.
Factors Binding SRE and APP Regions--
To assess the activity of
the SRE and APP sequences prior to and following growth arrest, we
performed mobility shift assays with SRE1, SRE2, and the APP
oligonucleotides. Nuclear extracts from growing or from 4-day-arrested
mouse fibroblasts were incubated with oligonucleotides containing the
SRE or APP sequences (Fig. 7). The APP
region that contributes to the induction of apoD expression during
growth arrest did not seem to bind any factor in our electrophoretic mobility shift assays (data not shown). With nuclear extracts isolated
from growing cells, SRE1 and SRE2 probes gave three retarded bands (A,
B, and D). All three bands were competed with a 25-fold excess of the
cold SRE1 or SRE2 oligonucleotide. The binding was also fully competed
with the c-fos SRE oligonucleotide. In contrast, the
SRE1 and SRE2 oligonucleotides, mutated in the SRE site, as well as an
unrelated oligonucleotide (UNR) were unable to abolish the binding.

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 7.
Nuclear extracts from growing (lanes
1-7) or 4-day serum-starved (lanes 8-14)
NIH/3T3 mouse fibroblasts were used in electrophoretic mobility assays
with probes containing the SRE1 (lanes 2-7 and
8-14) or SRE2 (lanes 1 and
5). The bands representing SRE-binding
complexes are labeled A, B, C, and
D. Unlabeled competitor nucleotides were added at 25-fold
molar excess (SRE1, lanes 3 and 10; mSRE1,
lanes 4 and 11; SRE c-fos, lanes
5 and 12; foreign DNA sequence UNR, lanes 6 and 13; SRE2, lanes 7 and 14).
Representative of three similar experiments.
|
|
With nuclear extracts isolated from growth-arrested cells, the same
bands A, B, and D were detected. Again, cold SRE1, SRE2, and the
c-fos SRE oligonucleotides were effective competitors whereas the mutated SRE and the UNR oligonucleotides did not compete. However, band B was much less intense than that observed with the
extracts from growing cells and an additional band (band C) with a
faster mobility was present.
 |
DISCUSSION |
We have previously shown that apoD expression is induced when
cultured human fibroblasts enter a quiescent or senescent state (35)
and, in a number of situations, apoD expression is absent in
proliferating cells and is induced in cells that undergo growth arrest.
In some aspects, growth arrest, such as that provoked by serum
deprivation, may be considered as a stress response for growing cells.
In exponentially non-transformed growing cells, withdrawal of serum
causes a fraction of the culture to undergo apoptosis. After an initial
wave of apoptosis, the remainder of the culture successfully enters
G0/G1 but does not enter into S phase (51-53).
ApoD expression is induced in several stress conditions, and a role as
an acute-phase protein has been proposed (17). Thus, the increased apoD
expression that follows growth arrest may represent a component of a
stress response to serum deprivation. Here, we have extended our
previous studies with human fibroblasts (35) to show that growth arrest
also induces apoD expression in primary mouse fibroblasts and in a
number of cell lines, including NIH/3T3 murine fibroblasts, ATCC 293 human fibroblast-like cells, COS transformed monkey kidney cells, and
U373MG human astrocytoma cells. ApoE expression is also increased in
these cells by serum starvation, which is interesting in view of the
apparent coordinate control of expression of apoD and apoE in a number
of pathophysiological situations. In contrast, apoD expression is not
induced by growth arrest in MCF-7 and ZR75-1 human breast cancer cells
nor in LNCap human prostate cancer cells. In the case of the MCF-7
cells, there is a dissociation of the response of apoD and apoE to
serum starvation with an inhibition of apoD gene expression
and an induction of apoE gene expression. ApoD expression in
some cell lines is modulated by estrogens, and the presence of
estradiol that was used to supplement the media of the human breast and
prostate cancer cells may have masked the effect of growth arrest on
apoD expression.
Analysis of constructs with progressive deletions from the 5' terminus
of the apoD promoter revealed that the region between nucleotides 179 and 4 is responsible for the basal gene expression, whereas the region from 558 to 179 is implicated in the modulation of apoD expression following growth arrest with little contribution of
sequences further upstream. Inclusion in the constructs of the
non-coding exon 1, which contains a transforming growth factor- inhibitory element, had an inhibitory effect on transcriptional activity in the presence and the absence of serum, and this was particularly apparent with the 1176/ 4 construct. Regulatory elements within non-coding exons have been identified in other genes
(54). Introduction of internal deletions within the apoD promoter confirmed the importance of the region 558 to 179 in the
response of apoD expression to growth arrest. Moreover, it is probable
that two or more distinct elements within the region participate in
this regulation as deletion of either the sequences 558 to 352 or
352 to 179 largely eliminates the serum-starvation-induced apoD
expression. The addition of the APP element restored about half of the
activity ( 525/ 310 and  266/ 51) suggesting a role for this
DNA element. When the APP was deleted from the 588/ 4 construct, the
induction of expression by growth arrest was reduced by about 80%. The
response of cells transfected with the  676/ 471,  548/ 321,
and  558/ 352 constructs to growth arrest suggests a potential
role for the two SRE elements located at 502 and 474. However,
mutation of one or both SREs in the 558/ 4 construct, with or
without deletion of the APP, had only a minor effect on inducibility of expression.
The abundance of regulatory elements in the proximal apoD
promoter complicates the interpretation of the results of experiments in which regions of the promoter are deleted. To study, in isolation, the role of the SRE and APP elements in the growth arrest induction of
apoD gene expression, one or more copies of the SRE and/or APP elements were placed upstream of the 179/ 4 minimal functional promoter. Constructs that contained either SREs or APPs showed increased expression of the reporter when transfected cells were deprived of serum. The magnitude of the induction was a function of the
number of copies of the individual elements in the promoter, and, when
placed in tandem, SREs and APPs gave additive effects. Although the
SREs and APPs were functional in both sense and antisense orientations,
induction was sensitive to the relative orientation of individual
elements within the promoter when multiple copies were present. These
results provide additional support for a role of the APP sequence in
the induction of apoD expression following growth arrest. The role of
the SREs in this phenomenon is less clear. When placed upstream of the
minimal apoD promoter, SREs confer growth arrest-induced
transcriptional activation, whereas deletion of SRE elements in the
558/ 4 construct had minimal effects on induction. It would appear,
therefore, that the contribution of the SREs to the induction depends
on their context within the apoD promoter.
The apoD APP sequence consists of 25 alternating purine-pyrimidine
pairs that are dominated by d(CA) pairs and is directly preceded by a
track of 14 pyrimidines. Because these characteristics correspond to
established criteria for Z-DNA formation (55-61), it is probable that
the APP element in the apoD promoter can form Z-DNA. Z-DNA
conformations and APP sequences have been associated with both
activation (62-65) and repression (66-70) of gene expression in
mammalian cells. It has been proposed that Z-DNA structures may
modulate transcription by providing binding sites for regulatory proteins that may recognize the Z-DNA conformation rather than a
specific sequence (71-73), by assuring the optimal spatial separation between successive RNA polymerases (74), by determining the orientation
of different transcription factors on the DNA helix (75), or by
altering internucleosomal DNA helical twist in chromatin (62). The
mechanism by which the APP in apoD promoter regulates gene
expression following growth arrest remains to be determined. Although
the electrophoretic mobility shift assays on the APP region did not
show any complex formation, the conditions of ionic strength may not
have been optimal for Z-DNA formation. It is unlikely that Z-DNA plays
a role in apoE gene expression, because no APP sequences
were identified in the 30 kbp of the 5'-flanking sequence of the
apoE gene (Human Genome, National Center for
Biotechnology Information).
Several studies have demonstrated that SREs can be the site of
regulation of both induction and repression events in serum-stimulated quiescent fibroblasts (76, for review see Ref. 77). It has been shown
that the serum-responsive factor (SRF) binds to the SRE in the
c-fos promoter as a homodimer (78). Binding of the SRF then
allows the binding of a second protein, initially called ternary
complex factor (TCF) that cannot bind to the SRE by itself. TCF, which
was identified by Shaw and co-workers (79), includes several different
proteins that contain an Ets domain with DNA-binding properties. Using
specific oligonucleotides containing the two SRE sequences and nuclear
extracts isolated from growing NIH/3T3 mouse fibroblasts, we obtained
three different bands, A, B, and D, that were identical for both
oligonucleotides (Fig. 7). This pattern is similar to that obtained by
Omoike and co-workers (80) who also worked with NIH/3T3 nuclear
extracts. The binding of these three entities looked specific, because
it was drastically decreased with the cold SRE1, SRE2, and the
c-fos SRE but not with mutated SRE1, SRE2, and an unrelated
oligonucleotide. The identity of band D is not known, and it is
reported as being nonspecific in some studies (80). Band B is believed
to be a dimer of SRF (48), and band A consists of the SRF homodimer and
an unknown factor (80), most likely a TCF member. A strong
collaboration between ETS proteins and the SRF has already been
proposed (81), and it is interesting to note that an Ets binding site
(EBS) is present at position 489, between the SRE1 and SRE2 (Fig. 3). In addition, an AP-1 element cooperates with the SRE to induce or
reduce c-fos expression in growing and quiescent cells,
respectively (82). An AP-1 element is present directly upstream of the
two SRE elements in the apoD proximal promoter (position
535 to 526). Using nuclear extracts isolated from 4-day
growth-arrested fibroblasts, we obtained the same three bands A, B, and
D. However, when compared with nuclear extracts from growing cells,
band B was greatly reduced in intensity and an additional band C of
faster mobility was observed. Hyperphosphorylation of SRF is thought to
be responsible for the inability of SRF to bind the SRE in senescent
human fibroblasts (83). It is possible that, in growth-arrested
fibroblasts, the transcription of the apoD gene is elicited
due to inactivation of SRF by hyperphosphorylation, which, in
turn, allows other factors such as stress proteins to bind to the SRE
and transactivate expression (Band C). SREs could also contribute to
the induction of apoE expression following growth arrest as deletion of
a part of the promoter that includes the two most distal SRE results in
a reduction of promoter activity (Fig. 6C).
Here we have identified elements within the apoD promoter
that contribute to the activation of transcription that occurs when cells enter growth arrest following serum deprivation. It will now be
important to identify the proteins that are involved in the
transactivation and to determine if these elements are involved in the
induction of apoD gene expression that occurs in
neuropathological situations and following experimental injury in the
peripheral and central nervous systems.
 |
ACKNOWLEDGEMENTS |
We thank Dr. Corinne Barat in the design of
some experiments and for helpful discussions. We gratefully acknowledge
support from the Canadian Institute for Health Research and the Heart and Stroke Foundation of Canada.
 |
FOOTNOTES |
*
This work was supported by the Canadian Institute for Health
Research (grants MT-9880 and MT-15677) and by the Heart and Stroke Foundation of Canada.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: Laboratoire de
Biologie Moléculaire, Département des Sciences Biologiques,
CP 8888 Succ Centre-ville, Université du Québec à
Montréal, Montréal H3C 3P8, Québec. Tel.:
514-987-3000 (Ext. 3953); Fax: 514-987-4647; E-mail:
Rassart.Eric@UQAM.CA.
Published, JBC Papers in Press, November 15, 2001, DOI 10.1074/jbc.M105057200
 |
ABBREVIATIONS |
The abbreviations used are:
apoD, apolipoprotein
D;
apoE, apolipoprotein E;
AP-1, activating protein 1;
APP, alternating
purine-pyrimidine stretch;
APRE, acute phase-responsive element;
ERE, estrogen-responsive element;
FSE, fat-specific element;
GRE, glucocorticoid-responsive element;
MOPS, 3-(N-morpholino)propanesulfonic acid;
PRE, progesterone-responsive element;
SDR, sterol-dependent
repressor;
SRE, serum-responsive element;
SRF, serum-responsive factor;
DMEM, Dulbecco's modified Eagle's medium;
UNR, unrelated sequence;
TCF, ternary complex factor;
EBS, Ets binding site.
 |
REFERENCES |
| 1.
|
Elshourbagy, N. A.,
Liao, W. S.,
Mahley, R. W.,
and Taylor, J. M.
(1985)
Proc. Natl. Acad. Sci. U. S. A.
82,
203-207[Abstract/Free Full Text]
|
| 2.
|
Drayna, D.,
Fielding, C.,
McClean, J.,
Baer, B.,
Castro, G.,
Chen, E.,
Comstock, L.,
Henzel, W.,
Kohr, W.,
Rhee, L.,
Wion, K.,
and Lawn, R.
(1986)
J. Biol. Chem.
261,
16535-16539[Abstract/Free Full Text]
|
| 3.
|
Provost, P. R.,
Weech, P. K.,
Tremblay, N. M.,
Marcel, Y. L.,
and Rassart, E.
(1990)
J. Lipid Res.
31,
2057-2065[Abstract]
|
| 4.
|
Smith, K. M.,
Lawn, R. M.,
and Wilcox, J. N.
(1990)
J. Lipid Res.
31,
995-1004[Abstract]
|
| 5.
|
Provost, P. R.,
Villeneuve, L.,
Weech, P. K.,
Milne, R. W.,
Marcel, Y. L.,
and Rassart, E.
(1991)
J. Lipid Res.
32,
1959-1970[Abstract]
|
| 6.
|
Terrisse, L.,
Séguin, D.,
Desforges, M.,
and Rassart, E.
(1995)
Brain Res. Mol. Brain Res.
30,
242-250[Medline]
[Order article via Infotrieve]
|
| 7.
|
Provost, P. R.,
Tremblay, Y., El-,
Amine, M.,
and Bélanger, A.
(1995)
Mol. Cell. Endocrinol.
109,
225-236[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Vieira, V.,
Lindstedt, K.,
Schneider, W.,
and Vieira, P. M.
(1995)
Mol. Reprod. Dev.
42,
443-446[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Cofer, S.,
and Ross, S.
(1996)
Gene
171,
261-263[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Ayrault-Jarrier, M.,
Levy, G.,
and Polonovski, J.
(1963)
Bull. Soc. Chem. Biol.
45,
703-713
|
| 11.
|
Bojanovsky, D.,
Alaupovic, P.,
McConathy, W. J.,
and Kelley, J. L.
(1980)
FEBS Lett.
112,
251-254[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Albers, J. J.,
Cheung, M. C.,
Ewens, S. L.,
and Tollefson, J. H.
(1981)
Atherosclerosis
39,
395-409[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Weech, P. K.,
Camato, R.,
Milne, R. W.,
and Marcel, Y. L.
(1986)
J. Biol. Chem.
261,
7941-7951[Abstract/Free Full Text]
|
| 14.
|
Camato, R.,
Marcel, Y. L.,
Milne, R. W.,
Lussier-Cacan, S.,
and Weech, P. K.
(1989)
J. Lipid Res.
30,
865-875[Abstract]
|
| 15.
|
Drayna, D.,
McLean, J. W.,
Wion, K. L.,
Trent, J. M.,
Drabkin, H. A.,
and Lawn, R. M.
(1987)
DNA (N. Y.)
6,
199-204[Medline]
[Order article via Infotrieve]
|
| 16.
|
Peitsch, M. C.,
and Boguski, M. S.
(1989)
The New Biologist
2,
197-206
|
| 17.
|
Rassart, E.,
Bedirian, A., Do,
Carmo, S.,
Guinard, O.,
Sirois, J.,
Terrisse, L.,
and Milne, R.
(2000)
Biochim. Biophys. Acta
1482,
185-198[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Lea, O. A.
(1988)
Steroids
52,
337-338[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Dilley, W. G.,
Haagensen, D. E.,
Cox, C. E.,
and Wells, S. A., Jr.
(1990)
Breast Cancer Res. Treatment
16,
253-260[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Milne, R. W.,
Rassart, E.,
and Marcel, Y. L.
(1993)
Curr. Opin. Lipidol.
4,
100-106[CrossRef]
|
| 21.
|
Cabral, J. H. M.,
Atkins, G. L.,
Sanchez, L. M.,
Lopez-Boado, Y. S.,
Lopez-Otin, C.,
and Sawyer, L.
(1995)
FEBS Lett.
366,
53-56[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Zeng, C.,
Spielman, A. I.,
Vowels, B. R.,
Leyden, J. J.,
Biemann, K.,
and Preti, G.
(1996)
Biochemistry
94,
6626-6630
|
| 23.
|
Boyles, J. K.,
Notterpek, L. M.,
and Anderson, L. J.
(1990b)
J. Biol. Chem.
265,
17805-17815[Abstract/Free Full Text]
|
| 24.
|
Boyles, J. K.,
Notterpek, L. M.,
Wardell, M. R.,
and Rall, S. C., Jr.
(1990a)
J. Lipid Res.
31,
2243-2256[Abstract]
|
| 25.
|
Terrisse, L.,
Poirier, J.,
Bertrand, P.,
Merched, A.,
Siest, G.,
Milne, R.,
and Rassart, E.
(1998)
J. Neurochem.
71,
1643-1650[Medline]
[Order article via Infotrieve]
|
| 26.
|
Suresh, S.,
Yan, Z.,
Patel, R. C.,
Patel, Y. C.,
and Patel, S. C.
(1998)
J. Neurochem.
70,
242-251[Medline]
[Order article via Infotrieve]
|
| 27.
|
Thomas, E. A.,
Dean, B.,
Pavey, G.,
and Sutcliffe, J. G.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
4066-4071[Abstract/Free Full Text]
|
| 28.
|
Spreyer, P.,
Schaal, H.,
Kuhn, G.,
Rothe, T.,
Unterbeck, A.,
Oleck, K.,
and Muller, H. W.
(1991)
EMBO J.
9,
2479-2484[Medline]
[Order article via Infotrieve]
|
| 29.
|
Ong, W. Y., He, Y.,
Suresh, S.,
and Patel, S. C.
(1997)
Neuroscience
79,
359-3567[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Terrisse, L.,
Séguin, D.,
Bertrand, P.,
Poirier, J.,
Milne, R.,
and Rassart, E.
(1999)
Brain Res. Mol. Brain Res.
70,
26-35[Medline]
[Order article via Infotrieve]
|
| 31.
|
Montpied, P.,
de Bock, F.,
Lerner-Natoli, M.,
Bockaert, J.,
and Rondouin, G.
(1999)
Epilepsy Res.
35,
135-146[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Aspinall, J. O.,
Bentel, J. M.,
Horsfall, D. J.,
Haagensen, D. E.,
Marshall, V. R.,
and Tilley, W. D.
(1995)
J. Urol.
154,
622-628[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Balbin, M.,
Freije, J. M.,
Fueyo, A.,
Sanchez, L. M.,
and Lopez-Otin, C.
(1990)
Biochem. J.
271,
803-807[Medline]
[Order article via Infotrieve]
|
| 34.
|
Dìez-Itza, I.,
Vizoso, F.,
Merino, A. M.,
Sanchez, L. M.,
Tolivia, J.,
Fernandez, J.,
Rubial, A.,
and Lopez-Otin, C.
(1994)
Am. J. Pathol.
144,
310-320[Abstract]
|
| 35.
|
Provost, P. R.,
Marcel, Y. L.,
Milne, R. W.,
Weech, P. K.,
and Rassart, E.
(1991)
FEBS Lett.
290,
139-141[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Simard, J.,
de Launoit, Y.,
Haagensen, D. E.,
and Labrie, F.
(1992)
Endocrinology
130,
1115-1121[Abstract/Free Full Text]
|
| 37.
|
Blais, Y.,
Sugimoto, K.,
Carrière, M.-C.,
Haagensen, D. E.,
Labrie, F.,
and Simard, J.
(1994)
Int. J. Cancer
59,
400-407[Medline]
[Order article via Infotrieve]
|
| 38.
|
Lòpez-Boado, Y. S.,
Tolivia, J.,
and Lopez-Otin, C.
(1994)
J. Biol. Chem.
269,
26871-26878[Abstract/Free Full Text]
|
| 39.
|
Patel, S. C.,
Asotra, K.,
Patel, Y.,
McConathy, W. J.,
Patel, R. C.,
and Suresh, S.
(1995)
Neuroreport
6,
653-657[Medline]
[Order article via Infotrieve]
|
| 40.
|
Lambert, J.,
Provost, P. R.,
Marcel, Y. L.,
and Rassart, E.
(1993)
Biochim. Biophys. Acta
1172,
190-192[Medline]
[Order article via Infotrieve]
|
| 41.
|
Lehrach, H.,
Diamond, D.,
Mosney, J. M.,
and Boedtker, H.
(1977)
Biochemistry
16,
4743[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Sambrook, J.,
Fritsch, E. F.,
and Maniatis, T.
(1989)
Molecular Cloning: A Laboratory Manual
, 2nd Ed.
, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
|
| 43.
|
Ding, W.,
Witte, M. M.,
and Scott, R. E.
(1999)
Cancer Res.
1,
3795-3802
|
| 44.
|
Sanger, F.,
and Coulson, A. R.
(1975)
J. Mol. Biol.
94,
441-448[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Graham, F. L.,
and van der Eb, A. J.
(1973)
Virology
52,
456-467[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Gorman, C. M.,
Moffat, L. F.,
and Howard, B. H.
(1982)
Mol. Cell. Biol.
2,
1044-1051[Abstract/Free Full Text]
|
| 47.
|
Dignam, J. D.,
Lebovitz, R. M.,
and Roeder, R. G.
(1983)
Nucleic Acids Res.
11,
1475-1489[Abstract/Free Full Text]
|
| 48.
|
Benson, B. A.,
Jonsen, M.,
and Benedict, S. H.
(1996)
Cell. Immunol.
170,
245-250[CrossRef][Medline]
[Order article via Infotrieve]
|
| 49.
|
Haagensen, D. E.,
and Mazoujian, G.
(1986)
in
Diseases of the Breast, 3rd Ed.
(Haagensen, C. D., ed)
, pp. 250-267, Saunders, Philadelphia, PA
|
| 50.
|
Treisman, R.
(1990)
Semin. Cancer Biol.
1,
47-58[Medline]
[Order article via Infotrieve]
|
| 51.
|
Jayadev, S.,
Liu, B.,
Bielawska, A. E.,
Lee, J. Y.,
Nazaire, F.,
Pushkareva, M. Y.,
Obeid, L. M.,
and Hannun, Y. A.
(1995)
J. Biol. Chem.
270,
2047-2052[Abstract/Free Full Text]
|
| 52.
|
Howard, M. K.,
Burke, L. C.,
Mailhos, C.,
Pizzey, A.,
Gilbert, C. S.,
Lawson, W. D.,
Collins, M. K.,
Thomas, N. S.,
and Latchman, D. S.
(1993)
J. Neurochem.
60,
1783-1791[CrossRef][Medline]
[Order article via Infotrieve]
|
| 53.
|
Shichiri, M.,
Hanson, K. D.,
and Sedivy, J. M.
(1993)
Cell Growth Differ.
4,
93-104[Abstract]
|
| 54.
|
Csiszar, K.,
Entersz, I.,
Trackman, P. C.,
Samid, D.,
and Boyd, C. D.
(1996)
Mol. Biol. Rep.
23,
97-108[CrossRef][Medline]
[Order article via Infotrieve]
|
| 55.
|
Eichman, B. F.,
Schroth, G. P.,
Basham, B. E.,
and Ho, P. S.
(1999)
Nucleic Acids Res.
27,
543-550[Abstract/Free Full Text]
|
| 56.
|
Kuramoto, N.,
Ogita, K.,
and Yoneda, Y.
(1999)
Jpn. J. Pharmacol.
80,
103-109[CrossRef][Medline]
[Order article via Infotrieve]
|
| 57.
|
McLean, M. J.,
Blaho, J. A.,
Kilpatrick, M. W.,
and Wells, R. D.
(1986)
Proc. Natl. Acad. Sci. U. S. A.
83,
5884-5888[Abstract/Free Full Text]
|
| 58.
|
Ho, P. S.,
Ellison, M. J.,
Quigley, G. J.,
and Rich, A.
(1986)
EMBO J.
5,
2737-2744[Medline]
[Order article via Infotrieve]
|
| 59.
|
Ellison, M. J.,
Feigon, J.,
Kelleher, R. J., 3rd,
Wang, A. H.,
Habener, J. F.,
and Rich, A.
(1986)
Biochemistry
25,
3648-3655[CrossRef][Medline]
[Order article via Infotrieve]
|
| 60.
|
Kim, S. Y.,
Berger, D.,
Yim, S. O.,
Sacks, P. G.,
and Tansky, M. A.
(1996)
Mol. Carcinog.
16,
6-11[CrossRef][Medline]
[Order article via Infotrieve]
|
| 61.
|
Nejedly, K.,
Lilley, D. M.,
and Palecek, E.
(1996)
J. Biomol. Struct. Dyn.
13,
1007-1014[Medline]
[Order article via Infotrieve]
|
| 62.
|
Krajewski, W. A.
(1995)
FEBS Lett.
358,
13-16[CrossRef][Medline]
[Order article via Infotrieve]
|
| 63.
|
Herrick, K. R.,
Gorin, F. A.,
Park, E. A.,
and Tait, R. C.
(1993)
Gene
126,
203-211[CrossRef][Medline]
[Order article via Infotrieve]
|
| 64.
|
Himelstein, B. P.,
Lee, E. J.,
Sato, H.,
Seiki, M.,
and Mushel, R. J.
(1998)
Clin. Exp. Metastasis
16,
169-177[CrossRef][Medline]
[Order article via Infotrieve]
|
| 65.
|
Wolfl, S.,
Martinez, C.,
Rich, A.,
and Majzoub, J. A.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
3664-3668[Abstract/Free Full Text]
|
| 66.
|
Delic, J.,
Onclercq, R.,
and Moisan-Coppey, M.
(1991)
Biochem. Biophys. Res. Commun.
181,
818-826[CrossRef][Medline]
[Order article via Infotrieve]
|
| 67.
|
Naylor, L. H.,
and Clark, E. M.
(1990)
Nucleic Acids Res.
18,
1595-1601[Abstract/Free Full Text]
|
| 68.
|
Santoro, C.,
Costanzo, F.,
and Ciliberto, G.
(1984)
EMBO J.
3,
1553-1559[Medline]
[Order article via Infotrieve]
|
| 69.
|
Gilmour, R. S.,
Spandidos, D. A.,
Vass, J. K.,
Gow, J. W.,
and Paul, J.
(1984)
EMBO J.
3,
1263-1272[Medline]
[Order article via Infotrieve]
|
| 70.
|
Hendrich, B. D.,
Plenge, R. M.,
and Willard, H. F.
(1997)
Nucleic Acids Res.
25,
2661-2671[Abstract/Free Full Text]
|
| 71.
|
Arndt-Jovin, D. J.,
Udvardy, A.,
Garner, M. M.,
Ritter, S.,
and Jovin, T. M.
(1993)
Biochemistry
32,
4862-4872[CrossRef][Medline]
[Order article via Infotrieve]
|
| 72.
|
Herbert, A.,
Lowenhaupt, K.,
Spitzner, J.,
and Rich, A.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
7550-7554[Abstract/Free Full Text]
|
| 73.
|
Herbert, A.,
and Rich, A.
(1999)
Genetica
106,
37-47[CrossRef][Medline]
[Order article via Infotrieve]
|
| 74.
|
Peck, L. J.,
and Wang, J. C.
(1985)
Cell
40,
129-137[CrossRef][Medline]
[Order article via Infotrieve]
|
| 75.
|
Rich, A.
(1994)
Ann. N. Y. Acad. Sci.
726,
1-16[CrossRef]
|
| 76.
|
Rivera, V. M.,
Sheng, M.,
and Greenberg, M. E.
(1990)
Genes Dev.
4,
255-268[Abstract/Free Full Text]
|
| 77.
|
Treisman, R.
(1994)
Curr. Opin. Genet. Dev.
4,
96-101[CrossRef][Medline]
[Order article via Infotrieve]
|
| 78.
|
Norman, C.,
Runswick, M.,
Pollock, R.,
and Treisman, R.
(1988)
Cell
55,
989-1003[CrossRef][Medline]
[Order article via Infotrieve]
|
| 79.
|
Shaw, P. E.,
Schroter, H.,
and Nordheim, A.
(1989)
Cell
56,
563-572[CrossRef][Medline]
[Order article via Infotrieve]
|
| 80.
|
Omoike, O. I.,
Benson, B. A.,
Chan, M. A.,
and Benedict, S. H.
(1999)
Biochem. Biophys. Res. Commun.
262,
523-529[CrossRef][Medline]
[Order article via Infotrieve]
|
| 81.
|
Ling, Y.,
West, A. G.,
Roberts, E. C.,
Lakey, J. H.,
and Sharrocks, A. D.
(1998)
J. Biol. Chem.
273,
10506-10514[Abstract/Free Full Text]
|
| 82.
|
Morgan, I. M.,
and Birnie, G. D.
(1992)
Cell Prolif.
25,
205-215[Medline]
[Order article via Infotrieve]
|
| 83.
|
Atadja, P. W.,
Stringer, K. F.,
and Riabowol, K. T.
(1994)
Mol. Cell. Biol.
14,
4991-4999[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. D. Carmo, D. Fournier, C. Mounier, and E. Rassart
Human apolipoprotein D overexpression in transgenic mice induces insulin resistance and alters lipid metabolism
Am J Physiol Endocrinol Metab,
April 1, 2009;
296(4):
E802 - E811.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Sasaki, H. Negishi, R. Koyama, N. Anbo, K. Ohori, M. Idogawa, H. Mita, M. Toyota, K. Imai, Y. Shinomura, et al.
p53 Family Members Regulate the Expression of the Apolipoprotein D Gene
J. Biol. Chem.,
January 9, 2009;
284(2):
872 - 883.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Do Carmo, H. Jacomy, P. J. Talbot, and E. Rassart
Neuroprotective Effect of Apolipoprotein D against Human Coronavirus OC43-Induced Encephalitis in Mice
J. Neurosci.,
October 8, 2008;
28(41):
10330 - 10338.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Belbin, J. L. Dunn, Y. Ling, L. Morgan, S. Chappell, H. Beaumont, D. Warden, D. A. Smith, N. Kalsheker, and K. Morgan
Regulatory region single nucleotide polymorphisms of the apolipoprotein E gene and the rate of cognitive decline in Alzheimer's disease
Hum. Mol. Genet.,
September 15, 2007;
16(18):
2199 - 2208.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Yue, N. Rasouli, G. Ranganathan, P. A. Kern, and T. Mazzone
Divergent Effects of Peroxisome Proliferator-activated Receptor {gamma} Agonists and Tumor Necrosis Factor {alpha} on Adipocyte ApoE Expression
J. Biol. Chem.,
November 12, 2004;
279(46):
47626 - 47632.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Sarjeant, A. Lawrie, C. Kinnear, S. Yablonsky, W. Leung, H. Massaeli, W. Prichett, J. P. Veinot, E. Rassart, and M. Rabinovitch
Apolipoprotein D Inhibits Platelet-Derived Growth Factor-BB-Induced Vascular Smooth Muscle Cell Proliferated by Preventing Translocation of Phosphorylated Extracellular Signal Regulated Kinase 1/2 to the Nucleus
Arterioscler. Thromb. Vasc. Biol.,
December 1, 2003;
23(12):
2172 - 2177.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|